There is currently no consensus on approaches to defining asthma or assessing asthma outcomes using electronic health record (EHR)-derived data. We explored these approaches in the recent literature, and examined the clarity of reporting.
Introduction
Asthma is in clinical practice a diagnosis based on the patient history, examination and objective tests [1] . It is however increasingly considered to represent a heterogeneous group of disorders with different phenotypes and endotypes [2] . The clinical definitions of asthma and its key outcomes, including disease severity, control, and attacks/exacerbations have been the subject of vigorous debate [3] [4] [5] [6] [7] [8] .
Particular challenges arise in the context of epidemiologic studies where validated operational definitions are needed [9, 10] . These studies are, increasingly, being undertaken using electronic health record (EHR)-derived data, which adds a further layer of complexity as the use of valid and reliable approaches is essential in order to ensure the reproducibility of research findings [11] .
In order to assess current approaches, we systematically interrogated the recent EHR-based asthma literature. Our specific objectives were to: i) describe the different methods of defining asthma and assessing disease severity, control and exacerbations in EHR-based studies; ii) investigate whether authors reported on the validity of those methods; and iii) assess their reporting practices. 3 
Results
We included 113 articles in the review. Figure 1 shows the study selection process. Most studies were conducted in the United States (US), Taiwan, and Canada (Table E3) , and employed longitudinal designs (Table E4 ). The most commonly used data types were health insurance claims followed by medical record repositories and dispensing databases (Table E5 ). 
Defining asthma
We identified 66 different algorithms to define asthma under seven diagnostic labels (Table E6) .
'Persistent asthma' was defined over 12 and 24 months using the US Healthcare Effectiveness Data and Information Set (HEDIS) criteria [14] , which involved assessing for any of the following asthma-related events: (1) emergency department (ED) visit, (2) hospitalisation, (3) outpatient visit and two asthma prescriptions, or (4) four asthma prescriptions [15] [16] [17] [18] ; by HEDIS criteria except "four asthma prescriptions" [19] ; and by any asthma encounter (hospitalisation or ED visit) or using oral corticosteroids (OCS) for three or more days [20] .
'Current asthma' was defined by any asthma encounter in the last three years [21] .
'Current general practitioner (GP)-reported and diagnosed asthma' was defined as any asthma encounter in the last 12 months, and 'current GP-reported, diagnosed and treated asthma' as the same plus any asthma prescription in the same period [22] .
Patients with treated asthma were otherwise required to have at least three dispensing events of asthma treatments in three different quarters of the year [23] .
'Acute asthma' was defined using any asthma diagnosis codes in ED or inpatient data [24] .
In the remaining studies, the label 'asthma' was defined using various algorithms, some of which were similar to those of the aforementioned more specific labels. 5 The intervals over which asthma diagnostic/management and prescription codes where queried were specified in 31 and 8 studies, respectively. The positions of diagnostic codes in the encounter (i.e. primary or secondary) were specified in 37 studies.
We identified five approaches in these algorithms: requiring diagnostic/management events, prescription events, or both (Table E7 ). In addition, to exclude likely non-asthma patients, some studies applied additional non-asthma criteria to restrict the study population based on age (Table E8 ) and/or comorbidities (Table E9 ).
Assessing asthma severity
Eighteen studies used 20 different algorithms to assess asthma severity (Table E10) , as binary (i.e. severe vs. non-severe asthma) [15, 23, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] or ordinal variables (mild, moderate, and severe asthma [39] ; or low, moderate, and high-risk asthma [40] ). The algorithms were based on one or more of the following asthma-related variables: number and/or dosage of prescriptions-namely SABA, inhaled corticosteroids (ICS), OCS, and leukotriene receptor antagonist (LTRA)-and number of hospitalisations, ED and outpatient visits. Almost all algorithms (17) used prescriptions (either alone or with other variables), while one algorithm was based only on hospitalisations and ED visits [36] . The intervals over which asthma severity was assessed were three [29] , six [38] , 12 [15, 23, 28, 30-32, 34, 36, 37, 39, 40] , 24 months [33, 35] , or unclear [26, 27] .
Assessing asthma control
Nine studies assessed asthma control using 11 algorithms, in 9 of which the interval was 12 months, in one 1-3 months, and in the remaining study this was unclear (Table E12) . Uncontrolled asthma was defined by a minimum number/dose of SABA prescriptions [30, 31, 39, 41, 42] ; any or short-course OCS prescriptions [30, 31, [41] [42] [43] [44] ; any hospitalisation or ED visit with either diagnosis of asthma [27, 30, 31, [41] [42] [43] 45] or -in already diagnosed asthma patients -diagnosis of status asthmaticus, pneumonia, dyspnoea, or respiratory insufficiency [30] ; unscheduled outpatient visits for asthma or lower respiratory tract infections (LRTI) [31] ; and GP consultations for LRTI requiring antibiotics in asthma patients [31] . Asthma impairment was defined based on the required SABA use, namely an average of more than two salbutamol puffs per day [31] . One study assessed asthma control based on number of OCS and SABA prescriptions per year (without giving any further details about the actual algorithm) [41] .
Defining exacerbations
Twenty-four studies defined exacerbations using EHR-derived data (Table E11) , as a dichotomous variable (absent vs. present) [16, 17, 23, 27, 30-32, 35, 37-39, 42-44, 46-54] , or stratified into absent, moderate and severe [55] . Oral corticosteroid prescriptions were used as a marker for exacerbations in 17 studies, either alone [23, 30, 31, 35, 39, 42, 47, 48, 53] or with a concurrent asthma encounter (e.g., a GP, outpatient, or ED visit, or hospitalisation within five or seven days) [16, 17, 32, 37, 38, 46, 52, 54] . In one study, exacerbations were defined by a minimum of six short-acting beta-2 agonist (SABA) prescriptions per year [47] . Other definitions included an outpatient code of 'asthma exacerbation' [52] , asthma hospitalisation [23, 30, 32, 35, 37, 39, 43, 44, 46, 48, 50, 51, [53] [54] [55] , asthma ED visit [16, 30-32, 35, 37, 38, 43, 44, 46, 48, 51-54] , or hospitalisation with diagnosis of status asthmaticus, or -in already diagnosed asthma patients -diagnosis of pneumonia, dyspnoea, or respiratory insufficiency [30] .
Clarity of reporting
Overall, the reporting of methodological aspects of using EHR-derived data was suboptimal. The majority of studies presented no information on the algorithms' validity. Among studies that reported on the validity, we identified 10 practices of reporting or justifying on the validity of algorithms (Table 1) : (1) performing validation or concordance analysis in the same study against other measures based on different data sources (e.g., medical record review or patientreported measures); (2) referring to previous validation of similar algorithms in the same or (3) different databases; (4) referring to previous validation of similar algorithms for different diseases in the same or (5) different database (6); using algorithms 'consistent' with previous studies in the same or (7) different databases; (8) using nationally developed algorithms; (9) using algorithms based on clinical guidelines; (10) and relying on previous validation of the database content. Some studies did not provide clear algorithms for asthma severity or control, but only referred to their components [23, 35, 37, 38, 41] .
Of the 113 reviewed studies, 40 studies used record-linkage, of which 17 mentioned it in the abstract, and 28 provided at least some explanation in the full text. The geographical region, time frame of data, and types or names of the data sources were mentioned in 83, 91, and 104 abstracts, respectively. Eighty-three studies reported their extent of access to the data sources. The intervals over which the algorithms were applied were often not reported. One hundred and eleven studies touched on the implications of using EHR data to study asthma. Of these, 64 and 63 studies discussed the risk of misclassification bias and unmeasured confounding, respectively. Six studies acknowledged the possible changes over time in data quality and coding practices and the entailing changes in case definition eligibility and accuracy. Five studies explained their data cleansing procedures. Finally, no study shared the programming codes of data preparation and analysis.
Discussion

Statement of principal findings
This systematic analysis of the contemporaneous asthma literature has found evidence of considerable international activity in using EHR-derived data to study a variety of asthma populations and outcomes. Importantly, we also found wide variations in the approaches used with limited attention being paid to the validity of the underlying algorithms used and suboptimal reporting of studies. This poses a major challenge to the interpretation and reproducibility of this important, emerging body of research inquiry.
Strengths and limitations
To our knowledge, this is the first systematic exercise to investigate the quality of reporting on EHR-based studies, especially the validity of measures, in the context of asthma. In undertaking this work, we used robust approaches which involved two people independently selecting studies and undertaking data extraction. The findings may also apply to other chronic diseases. This review had no geographic limits, but it was confined to assessing the recent literature.
Examining the most recent asthma literature is most likely to provide meaningful insights on current practices. A limitation is that we did not systematically check whether the references provided to support the claimed validity of algorithms in question actually provided sufficient evidence of validity. For example, differences might exist between the algorithms used in a given study and those previously validated.
Interpretation in the light of previous studies
Although EHR-derived data are convenient resources for research, they are originally collected for other purposes, and usually suffer from missing or incorrect data and potential biases [56] [57] [58] .
In addition, EHR systems usually fail to capture complete and accurate clinical information at the point of care due to design limitations and inefficient use of these systems by clinicians to document clinical data [59, 60] .
These issues impose challenges on their use to assess a complex and heterogeneous condition such as asthma. For example, asthma diagnosis codes, which are commonly used solely for patient identification, may be recorded after a trial or wrong diagnosis, and do not capture undiagnosed patients [61] . In addition, many EHR-derived databases often lack important variables, such as lung function, indication of dispensed medications, adherence to treatment, and lifestyle, which are vital for identifying and assessing asthma patients. These challenges are however not insurmountable. In this review, we found several techniques intended to improve algorithm accuracy such as age limitation, comorbidity exclusion, and diagnosis position restriction.
Ideally, algorithms should be validated in the databases in which they are used. However, this was often not the case. Instead, using algorithms with only reasonable face validity based on clinical guidelines or clinical judgement is a very common practice in EHR-based studies [62, 63] . These approaches assume that clinical codes in the database accurately represent the patient's actual health care events [62] .
Under-reporting on implementation details and methods' validity compromises transparency and reproducibility, a crucial issue in medical research. It has been previously found that in EHR-based studies, full lists of clinical codes were often not reported [64] . A recent, large-scale reproducibility exercise identified similar challenges due to suboptimal reporting of EHR-based studies, particularly sharing code lists and algorithms [65] .
The significant methodological heterogeneity we found in EHR-based asthma assessment algorithms reflects, in addition to the content differences between the databases used, the lack of consensus on the clinical definitions in the first place despite continuous standardisation efforts [5, 6, 66, 67] . The focus of our work was to examine asthma definitions and their validity specifically in the context of EHR, but this highlights the fundamental need to reach consensus on clinical asthma definitions and the appropriate validation of asthma diagnosis. For example, there is still an active debate on whether lung function is essential to establish asthma diagnosis [7, 8] . A recent study also found significant variation in algorithms to assess asthma severity from health insurance data [68] . Unjustified inter-study variation in the operational definitions of the same clinical concepts creates challenges for comparability, meta-analysis and evidence synthesis. These issues have been raised for asthma [69] and other allergic conditions such as peanut allergy [70, 71] and anaphylaxis [72] , where wide variations in findings were potentially attributed to inconsistent case definitions.
Implications for policy, practice and research
This review sheds light on the opportunities offered by the increasingly ubiquitous EHRs, but also highlights considerable heterogeneity and suboptimal reporting of EHR-based asthma assessment algorithms and the implications of these practices on comparability and reproducibility of studies.
Developing reliable algorithms to assess asthma outcomes using EHR data is a non-trivial challenge. In addition, standardising such algorithms across different populations may be impractical since databases differ in content, validity may not hold across different populations, and no best practice currently exists [68] . Similar challenges arise when comparing asthma epidemiology between multiple populations [73] . These methodologic issues, in addition to suboptimal reporting, should be considered when interpreting and synthesising evidence from geographically dispersed studies.
With the accelerating availability of EHR-derived data and their use to study asthma, we believe that consideration needs to be given to convening an international task force to work on the harmonisation of those algorithms under uniform and consistent clinical labels, while considering the differences between populations and databases. In addition, validation of these algorithms in the respective populations should be given a high priority. Furthermore, to allow more accurate assessment of asthma from EHR data, efforts are needed to improve the capture and coding of asthma-related data at the point of care [74] which requires more efficient EHR systems [59, 60] . In addition, emerging data sources such as patient-generated data and wearables need to be harnessed [75] . Finally, to improve the clarity of reporting on EHR-related methodological aspects, we strongly advocate the adoption of the RECORD Statement as an extension of the STROBE Statement by both authors and journal editors [13] . Optimal reporting should include complete code lists, detailed algorithms and validity assessment. Implications of using EHR-derived data to study a complex condition such as asthma should be clearly communicated to enable judgement of internal and external validity.
In summary, we have found that there is considerable international interest in exploiting EHRderived data to study asthma, but that there are considerable variations in the approaches used. These variations are compounded by sub-optimal reporting of methods, which makes it difficult to assess the reproducibility of research. Given the substantial investments taking place in EHRs globally, this body of work is likely to grow significantly in the coming years. It is therefore important that the asthma-interested research community works to place it on a solid footing in order to ensure the quality and reproducibility of this work.
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